Adjusted EPS also excludes certain other gains and losses that are either isolated or cannot be expected to occur again with any regularity or predictability, tax provisions/benefits related to the previous items, benefits from tax credit carryforwards, the impact of significant tax audits or events and the results of discontinued operations. Thermo Fisher's (TMO) acquisition of Patheon significantly strengthens its Pharmaceutical and Biotech business by adding complementary services. When typing in this field, a list of search results will appear and be automatically updated as you type. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent and pending acquisitions, including the acquisition of Patheon, may not materialize as expected; difficulty retaining key employees; and our ability to successfully implement integration strategies or to achieve expected synergies and operating efficiencies within the expected time-frames or at all. Patheon generated fiscal 2016 revenue of approximately $1.9 billion and will become part of Thermo Fisher's Laboratory Products and Services Segment. The stock has rallied roughly 19.04% over the last six months. King & Co., Inc., Thermo Fisher's information agent for the tender offer. Delisting is likely to reduce significantly the liquidity and marketability of any Patheon ordinary shares that have not been tendered pursuant to the tender offer. In addition, investors and shareholders of Patheon may obtain free copies of the tender offer materials by contacting D.F. Patheon has an extensive network of state-of-the-art facilities primarily in North America and Europe, and approximately 9,000 professionals worldwide. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods. With the closing of the deal, Patheon will be part of Thermo Fisher's Laboratory Products and Services segment. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Patheon also intends to terminate its reporting obligations under the Exchange Act by filing a Form 15 with the SEC on or about September 11, 2017. Announcement of the deal resulted in increases in Thermo Fisher and Patheon shares by 0.5% and 33.2%, respectively. Today, Thermo Fisher is acquiring approximately 95.3% of Patheon's outstanding ordinary shares. Patheon has requested that the New York Stock Exchange (the "NYSE") suspend trading of Patheon ordinary shares after the close of business on September 1, 2017, and Patheon intends to file a Form 25, Notification of Removal from Listing and/or Registration under Section 12(b) of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") with the SEC on such date. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. (Reuters) - Thermo Fisher Scientific Inc TMO.N said on Monday it would buy Patheon NV PTHN.N, a Dutch manufacturer of drugs for clinical trials, for $5.2 billion as it seeks to complement its. The tender offer referenced herein commenced on May 31, 2017. our Subscriber Agreement and by copyright law. Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including adjusted EPS and adjusted operating income, which exclude certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition and significant transaction costs; restructuring and other costs/income; and amortization of acquisition-related intangible assets. Patheon generated approximately $1.9 billion revenues in fiscal 2016. The tender offer referenced herein commenced on May 31, 2017. In this regard we note that Thermo Fisher's $4.2-billion buyout of FEI Company, which closed late in 2016, has helped Thermo Fisher to access FEI's industry leading high-performance electron microscopy platform used for protein study, facilitating life-science research. Email. Information about Thermo Fisher's directors and executive officers is set forth in the proxy statement for Thermo Fisher's 2017 annual meeting of stockholders, which was filed with the SEC on April 4, 2017. Dutch company Patheon, one of the largest pharmaceutical contract development and manufacturing organizations (CDMOs), is to be acquired by Thermo Fisher Scientific for $5.2 billion plus the assumption of $2 billion in net debt. Patheon pharma services provide industry-leading CDMO services as well as clinical trial solutions. Our Mission is to enable our customers to make the world healthier, cleaner and safer. "By adding Patheon's highly complementary CDMO capabilities to our leading clinical trials services and bioproduction technologies, we will be an even stronger partner for our pharmaceutical and biotech customers. Notably, Patheon is a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors. By providing your email address below, you are providing consent to Thermo Fisher Scientific Inc. to send you the requested Investor Email Alert updates. Additional Information and Where to Find It. ", Media Contact Information: Karen Kirkwood Phone: 781-622-1306 E-mail: [emailprotected] Website: www.thermofisher.com or Investor Contact Information: Ken Apicerno Phone: 781-622-1294 E-mail: [emailprotected]. , , , , , , Environmental, Social and Governance (ESG), HVAC (Heating, Ventilation and Air-Conditioning), Machine Tools, Metalworking and Metallurgy, Aboriginal, First Nations & Native American. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. Following delisting from the NYSE, Patheon ordinary shares will not be listed or registered on another national securities exchange. An integrated CDMO partner for every step in your drug development journey | Thermo Fisher Scientific provides industry-leading pharma services for drug . Through our premier brands Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. Additional Information and Where to Find It. In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including adjusted earnings per share (EPS) and adjusted operating income, which exclude certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition and significant transaction costs; restructuring and other costs/income; and amortization of acquisition-related intangible assets. fromJLLPartners,KoninklijkeDSMN.V. Additional acquisitions were made in 2015-2017, making Patheon a leading global producer of drug substances and drug products. You can seethe complete list of todays Zacks #1 Rank stocks here. Words such as "believes," "anticipates," "plans," "expects," "seeks," "estimates," and similar expressions are intended to identify forward-looking statements, but other statements that are not historical facts may also be deemed to be forward-looking statements. Thermo Fisher said it has already secured agreements with affiliates of JLL Partners and Royal DSM to support the deal. View Contact Info for Free. The transaction will take Thermo Fisher, a leading maker of scientific instruments and lab supplies, into a completely new market: pharmaceutical contract development and manufacturing. You can sign up for additional alert options at any time. 4 Surprising Tech Stocks to Keep an Eye On. According to a report by Markets and Markets,the global laboratory equipment services market is estimated to reach $11.51 billion by 2021, at a CAGR of 10.0% during 2016-2021. Details of the 2017 impact will be provided during Thermo Fisher's third quarter earnings call in late October. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industry, today announced that to boards of directors possess approve Thermo Fisher's acquisition of Patheon . Our mission is to enable our customers to make the world healthier, cleaner and safer. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Copy and paste multiple symbols separated by spaces. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. The timing and amount of these items are uncertain and could be material to Thermo Fisher's results computed in accordance with GAAP. Patheon provides comprehensive, integrated and highly customizable solutions as well as the expertise to help biopharmaceutical companies of all sizes satisfy complex development and manufacturing needs. ", To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-to-acquire-patheon-a-leading-contract-development-and-manufacturing-organization-cdmo-300457324.html, 781.622.1111 Patheon generated approximately $1.9 billion revenues in fiscal 2016. Based on information provided by American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, a total of 138,406,058 Patheon ordinary shares, representing approximately 95.3% of the outstanding Patheon ordinary shares, had been validly tendered and had not been properly withdrawn as of the Expiration Time (excluding 176,509 ordinary shares, representing approximately 0.12% of the aggregate number of ordinary shares outstanding, tendered pursuant to guaranteed delivery procedures that have not yet been delivered in settlement or satisfaction of such guarantee). Pat Griffin's Phone Number and Email. Thermo Fisher Scientific assumed operational responsibility for the facility in October 2021 under a . This copy is for your personal, non-commercial use only. We are confident that our combined offerings and Thermo Fisher's proven track record of disciplined M&A and successful integrations will take our business to the next level. Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.